利用冠状病毒病（COVID-19）患者样本评估商业和自动化 SARS-CoV-2 IgG 和 IgA ELISA 检测方法。
Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples.
机构信息
Department of Virology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Infectious diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
出版信息
Euro Surveill. 2020 May;25(18). doi: 10.2807/1560-7917.ES.2020.25.18.2000603.
Antibody-screening methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be validated. We evaluated SARS-CoV-2 IgG and IgA ELISAs in conjunction with the EUROLabworkstation (Euroimmun, Lübeck, Germany). Overall specificities were 91.9% and 73.0% for IgG and IgA ELISAs, respectively. Of 39 coronavirus disease patients, 13 were IgG and IgA positive and 11 IgA alone at sampling. IgGs and IgAs were respectively detected at a median of 12 and 11 days after symptom onset.
抗体筛查方法来检测严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）需要进行验证。我们评估了 SARS-CoV-2 IgG 和 IgA ELISA 与 EUROLabworkstation（Euroimmun，吕贝克，德国）的联合使用。总体特异性分别为 IgG 和 IgA ELISA 的 91.9%和 73.0%。在 39 名冠状病毒病患者中，13 名患者在采样时 IgG 和 IgA 均为阳性，11 名仅 IgA 阳性。IgG 和 IgA 分别在症状出现后 12 天和 11 天的中位数检测到。
Zotero 插件